Merck (Merck) pharmaceutical companies are developing a new drug anacetrapib, this drug can reduce the body "bad" LDL cholesterol levels, but also to enhance the "good" HDL cholesterol levels. Analysts estimate that, anacetrapib potential market value of more than 1 year and 10 billion U.S. dollars.
Anacetrapib can inhibit an enzyme called CETP activity, the enzyme can be good cholesterol into bad cholesterol.
Included in 1623 in a clinical trial in patients, anacetrapib experimental group of patients that allows the body's bad cholesterol reduced 39.8% (compared with the control group). Even more alarming is that, anacetrapib also allows volunteers to increase 138.1% of the good cholesterol. Results were published in the November 17 "New England Journal of Medicine" on.
But it is difficult to say whether anacetrapib heart health. Merck & Co. prepared to invest 100 million 5 thousand dollars, to complete a larger scale clinical trials, testing will include 30,000 volunteers. The pilot scheme was completed in 2015. Only then can decide whether Merck to the U.S. Food and Drug Administration (FDA) new drug application submission.
Biochemical improvement is that we want to see, but in the perspective of evaluating drugs, the light has biochemical indicators of the "improvement" is not enough, more convincing is the head-to reduce cardiovascular disease and mortality reduction. So take a long time a large sample of clinical trials to confirm this.
No comments:
Post a Comment